$650-Million to NYU From Drug Rights

By RICHARD MONASTERSKY

New York University has announced it will receive $650-million in return for selling a portion of its future royalty rights from sales of a drug called Remicade, which is used to fight rheumatoid arthritis and several other autoimmune diseases.

The drug, which is based on a 1989 discovery by two NYU researchers, has already earned the...